Sign In
Buy CARM
$0.0001
+0 (+0%)
At Close: Jun 03, 2026
Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference
07:30am, Wednesday, 05'th Feb 2025
PHILADELPHIA , Feb. 5, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced that Steven Kelly, Presi
Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline
08:30am, Monday, 09'th Dec 2024
Resources realigned to focus primarily on in vivo macrophage engineering platform for fibrosis, oncology and autoimmune disease therapies Development of CT-0525 to be discontinued; workforce reduced
Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
07:30am, Wednesday, 27'th Nov 2024
PHILADELPHIA , Nov. 27, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing in
New preclinical results support the anti-fibrotic potential of engineered macrophages in multiple fibrosis models Engineered TIM4-expressing macrophages correct defective efferocytosis in MASH, demon
Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma
07:30am, Friday, 08'th Nov 2024
New findings showcase the potential of in vivo CAR-M technology as an effective, off-the-shelf treatment for hepatocellular carcinoma (HCC) PHILADELPHIA , Nov. 8, 2024 /PRNewswire/ -- Carisma Therapeu
Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
07:30am, Thursday, 07'th Nov 2024
Initial results from the Phase 1 study of CT-0525, lead product candidate, expected in the first quarter of 2025 Nomination of a development candidate for liver fibrosis program expected in the first
Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024
09:05am, Tuesday, 05'th Nov 2024
Pre-clinical data demonstrate robust anti-tumor activity and a novel off-the-shelf approach for GPC3+ solid tumors PHILADELPHIA , Nov. 5, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM
Carisma Therapeutics Announces Changes to its Board of Directors
04:30pm, Wednesday, 30'th Oct 2024
Appointment of Sohanya Cheng Resignation of Michael Torok PHILADELPHIA , Oct. 30, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biophar
Carisma Therapeutics Announces Upcoming Presentations at SITC 2024
09:05am, Friday, 04'th Oct 2024
PHILADELPHIA , Oct. 4, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing inn
Carisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases
07:30am, Tuesday, 10'th Sep 2024
Building on successful pre-clinical in vivo CAR-M data in oncology, the companies will develop in vivo CAR-M for autoimmune diseases Moderna nominated two autoimmune disease targets under the collabo
Carisma Therapeutics to Present at Upcoming Conferences
07:30am, Tuesday, 03'rd Sep 2024
PHILADELPHIA , Sept. 3, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing inn
CARISMA THERAP (CARM) Upgraded to Buy: What Does It Mean for the Stock?
01:00pm, Tuesday, 13'th Aug 2024
CARISMA THERAP (CARM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Carisma Therapeutics Inc. (CARM) Reports Q2 Loss, Tops Revenue Estimates
10:00am, Thursday, 08'th Aug 2024
Carisma Therapeutics Inc. (CARM) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.49 per share a year ago.
Carisma Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
07:30am, Thursday, 08'th Aug 2024
Initial data for CT-0525, lead product candidate for anti-HER2 program, expected by year-end 2024 Nomination of a development candidate for liver fibrosis program expected in the first quarter of 2025
PHILADELPHIA , Aug. 6, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing in
